Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Misclassification in administrative claims data: quantifying the impact on treatment effect estimates
The SURPASS-CVOT trial is a phase 3, randomized, double-blind cardiovascular outcomes trial that will assess tirzepatide for both non-inferiority and superiority against dulaglutide. For dulaglutide, this effect is already proven: According to the Trulicity website, the drug may be used in adults with type 2 diabetes to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors. How do I know which medication is right for me
Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
The most frequent issues include nausea, vomiting, diarrhea, constipation, and upset stomach
The drugs lack of efficacy in this context does not preclude its potential utility in the broader, more heterogeneous population of older adults experiencing cognitive decline, where vascular and metabolic factors frequently play a major role
US$ 24.98
US$ 20.34
US$ 27.04
US$ 23.98
US$ 20.23
US$ 27.10
US$ 26.50
US$ 22.96
